Table 5.
Number (proportion) of participants with indication for treatment revision by country and treatment group
| Treatment group* | ||
|---|---|---|
| Control | Implementation | |
| Austria | ||
| Total number of patients | 308 | 277 |
| N (%) with indication for revision | ||
| Baseline | 293 (95.1) | 264 (95.3) |
| Follow-up | 111 (36.0) | 46 (16.6) |
| Italy | ||
| Total number of patients | 171 | 164 |
| N (%) with indication for revision | ||
| Baseline | 149 (87.1) | 148 (90.2) |
| Follow-up | 81 (47.4) | 29 (17.7) |
| Norway | ||
| Total number of patients | 165 | 170 |
| N (%) with indication for revision | ||
| Baseline | 147 (89.1) | 154 (90.6) |
| Follow-up | 53 (32.1) | 39 (22.9) |
| Spain | ||
| Total number of patients | 128 | 153 |
| N (%) with indication for revision | ||
| Baseline | 105 (82.0) | 146 (95.4) |
| Follow-up | 48 (37.5) | 33 (21.6) |
| Sweden | ||
| Total number of patients | 128 | 70 |
| N (%) with indication for revision | ||
| Baseline | 99 (77.3) | 69 (98.6) |
| Follow-up | 69 (53.9) | 19 (27.1) |
| Overall | ||
| Total number of patients | 900 | 834 |
| N (%) with indication for revision | ||
| Baseline | 793 (88.1) | 781 (93.7) |
| Follow-up | 362 (40.2) | 166 (19.9) |
*
Control = usual care; implementation = structured treatment pathway.